Описание товара
Показания
Indicated as maintenance treatment for advanced ovarian, fallopian tube, or primary peritoneal cancer that has responded to platinum-based chemotherapy, particularly in patients with HRD-positive disease or a germline BRCA mutation.
Механизм действия
PARP , PARP-1 PARP-2, DNA , PARP PARP-DNA , DNA BRCA1/2 BRCA1/2 HRD BRCA1/2 ,
Фармакология
12.1 Как это работает PARP , PARP-1 PARP-2, DNA , PARP PARP-DNA , DNA BRCA1/2 BRCA1/2 HRD BRCA1/2 ,
Способ применения
2.1 BRCA2 AKEEGA mCSPC [ (14.1)] BRCA AKEEGA mCRPC [ (14.2)] FDA , BRCA2 (BRCA2m) (mCSPC) AKEEGA 200 mg /1000 mg , 5 mg , BRCA BRCAm mCRPC AKEEGA 200 /1,
Меры предосторожности
5.1 / AKEEGA / (MDS/AML) AMPLITUDE MAGNITUDE , AKEEGA ,MDS AML 0.6% (2/347) 0.5% (1/212), AKEEGA MDS/ AML , / DNA MDS/AML , MDS/AML, AKEEGA
Лекарственные взаимодействия
7.1 AKEEGA CYP3A4 CYP3A4 [ (12.3)] CYP3A4 CYP3A4 [ (12.3)], 7.2 AKEEGA CYP2D6 , CYP2D6 ,
Условия хранения
AKEEGA® AKEEGA 50 /500 , , , “N 50 A”, 60 NDC 57894-050-60 AKEEGA 100 /500 , , , “N 50 A”,

